3 types, based on identification of serum autoantibodies
Clinical Issues
•
Affects patients of all ages, predominantly women
•
Chronic disease by definition but may present clinically as acute or fulminant hepatitis
Ongoing hepatic injury and scarring with development of cirrhosis and end-stage liver disease
•
Many patients have concurrent autoimmune diseases affecting other organs
•
Laboratory tests
Elevated transaminases
Serum autoantibodies
Polyclonal hypergammaglobulinemia
•
1st-line therapy is immunosuppression with corticosteroids in combination with azathioprine
Most patients improve dramatically with treatment
–
65% of patients achieve clinical, biochemical, and histologic remission within 3 years
•
Liver transplantation indicated for patients with fulminant hepatitis or decompensated end-stage disease
Microscopic
•
Untreated autoimmune hepatitis (AIH) usually presents chronic hepatitis with marked interface activity and lobular injury
•
Plasma cells may be prominent but are not constant feature of AIH
•
Treated disease may present with normal biopsy or mild chronic hepatitis without specific histologic features
•
Severe AIH may mimic acute viral hepatitis
•
Extent of inflammation and injury (“grade”) and scarring (“stage”) may be scored
TERMINOLOGY
Abbreviations
•
Autoimmune hepatitis (AIH)
Definitions
•
Ongoing hepatitis presumed autoimmune in etiology
•
3 types, based on identification of serum autoantibodies
Type 1
–
Antinuclear antibodies (ANA) &/or antismooth muscle antibodies (SMA)
–
Bimodal age distribution with peaks from 10-20 and 45-70 years of age
Type 2
–
Antiliver/antikidney microsomal antibodies (anti-LKM-1)
–
Most commonly affects children (ages 2-14) but also affects adults
–
More severe disease with greater frequency of relapse
Type 3
–
Soluble liver antigen (anti-SLA) or liver pancreas antigen (LP) antibodies
–
Usually affects adults aged 30-50
Subtyping of AIH is of descriptive value only and has no bearing on disease management
ETIOLOGY/PATHOGENESIS
Inciting Event Unknown
•
May include infectious agents, drugs, or toxins
•
Ongoing immune-mediated liver cell destruction
CLINICAL ISSUES
Epidemiology
•
Incidence
0.1-1.0 per 100,000 per year in North American and European populations
•
Age
Affects patients of all ages, including children and adolescents
•
Sex
Strong female predominance
•
Ethnicity
All ethnicities affected
Presentation
•
Chronic disease by definition but may present clinically as acute or fulminant hepatitis
Patients with acute onset of symptoms often found to have clinical, laboratory, &/or histologic signs of chronic liver disease
Acute presentation may represent flare of previously subclinical disease
Some patients have no evidence of chronic liver disease, appear clinically similar to acute viral or drug-related hepatitis
•
Common signs and symptoms
Fatigue and lethargy
Upper abdominal discomfort
Hepatomegaly
Jaundice
•
Many patients have concurrent autoimmune diseases affecting other organs